Full-Time
Principal/Senior Scientist
mRNA Engineering
NewLimit
51-200 employees
Develops epigenetic medicines to extend healthspan
Compensation Overview
$170k - $200k/yr
San Bruno, CA, USA
In Person
PhD
 Biology & Biotech (1) |
|---|
Get referred to NewLimit
See people who can refer or advise you
- PhD in molecular biology, biochemistry, cell biology, or a related field or equivalent industry experience (5+ years)
- Deep hands-on experience with in vitro transcription and the specific challenges of scaling nucleic acid production
- Proficiency with tangential flow filtration and chromatography systems for the purification of large scale RNA batches
- Ability to perform and interpret mRNA quality control assays and troubleshoot mRNA production challenges
- Strong experience in drafting technical reports and standardized protocols
- Execute and scale end-to-end mRNA production, including template preparation, in vitro transcription (IVT), and purification (TFF, chromatography)
- Implement rigorous quality control assays, including direct RNA sequencing, fragment analysis, dsRNA quantitation, and residual contaminant analysis
- Author and maintain detailed standard operating procedures and batch records, ensuring all production runs meet GLP standards
- Independently design and execute experiments to improve mRNA sequence potency, specificity, and manufacturing performance
- Train, manage, and mentor other team members on mRNA optimization and production workflows
- Familiarity with Python or R for sequence analysis and secondary structure prediction
- Understanding of how mRNA quality attributes impact Lipid Nanoparticle (LNP) formulation and delivery
- Experience with complex plasmid design and bacterial scale-up for DNA template generation
- Experience managing external contract manufacturing organizations (CMOs)
NewLimit develops medicines that aim to extend healthy years by reprogramming the epigenome of aging cells. It works by identifying aging-related epigenetic changes using single-cell genomics, machine learning, and high-throughput functional assays, then creating interventions to reverse those changes in targeted tissues such as the immune system and liver. Compared with others, NewLimit combines a specific focus on epigenetic reprogramming with a data-driven, tissue-targeted pipeline and pursues partnerships with pharma and biotech players to develop its proprietary medicines. Its goal is to deliver a new class of medicines that significantly increases the healthspan for patients with age-related diseases.
Company Size
51-200
Company Stage
Series C
Total Funding
$650M
Headquarters
South San Francisco, California
Founded
2022
Get referred to NewLimit
See people who can refer or advise you
Simplify's Take
What believers are saying
- NewLimit reported prototype medicine reversing age in old human liver cells in June 2026.
- The company scaled manufacturing more than 120X and prepared pivotal nonclinical studies.
- Founders Fund, Thrive Capital, Greenoaks, Kleiner Perkins, and Eli Lilly backed the round.
What critics are saying
- Human data start in 2027; any toxicity or no-efficacy signal kills the thesis quickly.
- LNP-mRNA reprogramming faces oncogenic and teratoma concerns if expression escapes transient control.
- Retro Biosciences and other longevity startups are funding faster, pressuring NewLimit to prove superiority.
What makes NewLimit unique
- Brian Armstrong and Blake Byers backed NewLimit through a $435M Series C in June 2026.
- NewLimit targets epigenetic reprogramming, not single diseases, with liver, immune, and vascular franchises.
- Its AI-driven genomics platform discovers transcription-factor combinations that restore youthful function in old cells.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
Dental Insurance
Vision Insurance
401(k) Retirement Plan
401(k) Company Match
Paid Parental Leave
Unlimited Paid Time Off
Growth & Insights and Company News
6 month growth
↓ -1%1 year growth
↑ 3%2 year growth
↑ 0%NewLimit raises $435M in Series C funding. June 3, 2026 NewLimit, a San Francisco, California-based developer of cell reprogramming and epigenetic longevity medicines, raised $435m in Series C funding. The round was led by Founders Fund, with participation from Thrive Capital, Greenoaks, Quiet Capital, Kleiner Perkins, Abstract, Nat Friedman, Daniel Gross, Valor Equity Partners, Eli Lilly Ventures, and Human Capital. The company intends to use the funds to advance its portfolio of age-reprogramming therapies, expand its computational biology teams, and transition its lead liver-cell program into its first human clinical studies. Led by Co-Founders Brian Armstrong and Blake Byers, alongside CEO and President Jacob Kimmel, NewLimit develops an AI-driven genomics platform designed to discover transcription factor combinations that reverse cellular aging and restore metabolic, vascular, and immune health. The company has discovered a prototype medicine that reverses cellular age in old human liver cells and has accelerated its development timeline to initiate its first investigator-led human trials in late 2027. Don't just read the news. Own the data. Stop manually tracking deals. Access this round and over 100 others this week - in our structured Master Database (XML) + Weekly Intelligence PDF. [Access FinSMEs Intelligence Hub] 03/06/2026
NewLimit raises USD 435m Series C to advance aging reprogramming medicine toward human trials. June 2, 2026 South San Francisco-based NewLimit, a biotechnology company focused on longevity medicine, has closed a USD 435 million Series C funding round as it prepares to bring its first aging reprogramming therapy into human clinical trials. Founders Fund led the round, joined by new investors Thrive Capital, Greenoaks, and Quiet Capital. Returning investors included Kleiner Perkins, Abstract, Nat Friedman and Daniel Gross, Valor Equity Partners, Eli Lilly Ventures, and Human Capital, among others. The company said it plans to use the capital to advance its lead program - a prototype medicine designed to reverse cell age in old human liver cells - into first-in-human trials, which the company indicated are expected to begin next year. According to NewLimit's operating plan, the lead program is based on lipid nanoparticle-delivered RNA medicines designed to transiently express combinations of transcription factors in aged liver cells. The initial focus is alcohol-related liver disease, a setting where aging hepatocytes lose regenerative capacity and become increasingly susceptible to injury. The company has reported identifying multiple reprogramming payloads that restore youthful function in preclinical liver models with one of those selected for further development. NewLimit argues that its work represents one of the most advanced efforts in the emerging field of partial cellular reprogramming, which remains largely preclinical despite substantial investor interest. If the company proceeds on its stated timeline, it would represent one of the first direct tests of an epigenetic reprogramming approach in human subjects. The financing ranks among the largest private biotech rounds completed this year and underscores continued investor enthusiasm for longevity-focused drug development. The scale of the Series C reflects broader momentum in longevity-focused biotech, where investors have shown increasing appetite for programs targeting the biology of aging itself rather than individual age-related diseases. Eli Lilly Ventures' continued participation is notable, given Lilly's expanding interest in metabolic and age-related biology following the commercial success of its GLP-1 franchise.
We’ve closed a $435M Series C led by Founders Fund alongside new investors Thrive Capital, Greenoaks, and Quiet Capital, and returning investors Kleiner Perkins, Abstract, Nat Friedman/Daniel Gross, Valor Equity Partners, Eli Lilly Ventures, Human Capital, and others.
NewLimit raises $435 million, tripling valuation to $3.1 billion
NewLimit, an anti-aging startup founded in 2021 by Coinbase CEO Brian Armstrong, has raised $45 million in new funding, valuing the company at $1.62 billion. The round comes just five months after its Series B, demonstrating rapid growth and strong investor confidence. The company focuses on extending human healthspan by treating age-related diseases. The fresh capital will support groundwork for future clinical studies to advance its technological capabilities. Competition in the longevity sector is intensifying, with OpenAI CEO Sam Altman investing $180 million in rival Retro Biosciences. Despite a 2025 downturn in anti-aging research stocks, NewLimit's successful funding round highlights investor belief in the sector's long-term potential and suggests continued capital flow into this emerging market.